Skip to main content

Research Repository

Advanced Search

MDM2 expression in the progression of Barrett’s oesophagus

Robinson, Leora; Ilyas, Mohammad; Ragunath, Krish; Card, Timothy R.; Abradu-Berchie, Berice; Kaye, Philip


Leora Robinson

Krish Ragunath

Clinical Associate Professor

Berice Abradu-Berchie

Philip Kaye


Barrett's oesophagus (BO) is the main precursor for oesophageal adenocarcinoma (OAC), and dysplasia arising within it is the standard marker used to predict risk of malignant progression. However, dysplasia diagnosis is subject to a significant amount of interobserver variation. Biomarkers may aid the diagnosis of dysplasia and may help predict the risk of progression to OAC. Abnormal expression of p53 can be reproducibly detected by immunohistochemistry (IHC) and it is an effective marker of risk of OAC1. There is however still a need for additional early stage markers.


Robinson, L., Ilyas, M., Ragunath, K., Card, T. R., Abradu-Berchie, B., & Kaye, P. (2018). MDM2 expression in the progression of Barrett’s oesophagus. Histopathology, 72(7), 1230-1233.

Journal Article Type Article
Acceptance Date Feb 2, 2018
Online Publication Date Feb 10, 2018
Publication Date Jun 30, 2018
Deposit Date Feb 7, 2018
Publicly Available Date Feb 11, 2019
Journal Histopathology
Print ISSN 0309-0167
Electronic ISSN 1365-2559
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 72
Issue 7
Pages 1230-1233
Keywords Barret’s oesophagus; MDM2; p53; Dysplasia
Public URL
Publisher URL
Additional Information This is the peer reviewed version of the following article: Robinson, L., Ilyas, M., Ragunath, K., Card, T., Abradu-Berchie, B. and Kaye, P. (), MDM2 Expression in the Progression of Barrett's Oesophagus. Histopathology. Accepted Author Manuscript. doi:10.1111/his.13480
, which has been published in final form at This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.


You might also like

Downloadable Citations